SB-01 is under clinical development by Spine BioPharma and currently in Phase III for Chronic Low Back Pain (CLBP). According to GlobalData, Phase III drugs for Chronic Low Back Pain (CLBP) have a 25% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how SB-01’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

SB-01 overview

SB-01 is under development for the treatment of degenerative disc disease (DDD) and chronic low back pain. The drug candidate is administered as an intradiscal injection. It is a synthetic peptide and targets TGF beta 1. It is developed based on knowledge-based in silico drug discovery platform called KISDD. The drug candidate is a new chemical entity.

Spine BioPharma overview

Spine BioPharma is a developer of a non-surgical solution that will remove pain and restore functionality. Spine BioPharma is headquartered in New York City, New York, the US.

For a complete picture of SB-01’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.